Grundläggande statistik
| CIK | 1093649 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Idenix Pharmaceuticals Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 15, 2014 |
IDIX / Idenix Pharmaceuticals Inc 15-12G - - FORM 15 Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-49839 Idenix Pharmaceuticals, Inc. (Exact name of registrant as |
|
| August 12, 2014 |
IDIX / Idenix Pharmaceuticals Inc / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015 With a copy to: Peter Harwich Allen & Overy L |
|
| August 12, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Baupost Group LLC/MA - IDIX13DAMEND2.PDML Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title Class of Securities) 45166R204 (Cusip Number) Seth A. Klarman The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700 Boston, Massachusetts 02116 (617) 210-8300 With a copy to: Jeffrey R. Katz, Esq Rop |
|
| August 6, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - AMENDMENT NO. 8 TO SCHEDULE TO Amendment No. 8 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Fil |
|
| August 5, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2014 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc SC 14D9/A - - AMENDMENT NO. 7 TO SCHEDULE 14D-9 Amendment No. 7 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
RESTATED CERTIFICATE OF INCORPORATION IDENIX PHARMACEUTICALS, INC. EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF IDENIX PHARMACEUTICALS, INC. FIRST: The name of the corporation is Idenix Pharmaceuticals, Inc. (hereinafter, the “Corporation”). SECOND: The address of the corporation’s registered office is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its registered agent at such address is |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
Merck Completes Tender Offer to Acquire Idenix EX-99.(a)(1)(J) Exhibit 99.(a)(1)(J) News Release FOR IMMEDIATE RELEASE Media Contacts: Pamela Eisele (267) 305-3558 Steve Cragle (908) 423-3461 Investor Contacts: Joe Romanelli (908) 423-5185 Justin Holko (908) 423-5088 Merck Completes Tender Offer to Acquire Idenix WHITEHOUSE STATION, N.J., Aug. 5, 2014 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the success |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - AMENDMENT NO. 7 Amendment No. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (id |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
IDIX / Idenix Pharmaceuticals Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on August 5, 2014 Registration No. |
|
| August 5, 2014 |
THIRD AMENDED AND RESTATED BYLAWS IDENIX PHARMACEUTICALS, INC. ARTICLE I - STOCKHOLDERS EX-3.2 Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF IDENIX PHARMACEUTICALS, INC. ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Boa |
|
| July 31, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Com |
|
| July 31, 2014 |
EX-10.1 Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 29th day of May, 2014, by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”), and IDENIX PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant entered into that certain Lease dated as of September 25 |
|
| July 31, 2014 |
IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2014 FINANCIAL RESULTS CAMBRIDGE, Mass., July 31, 2014 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported |
|
| July 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 29, 2014 |
IDIX / Idenix Pharmaceuticals Inc / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Rebecca Weston Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 324 7015 With a copy to: Peter Harwich Allen & Overy L |
|
| July 24, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identify |
|
| July 24, 2014 |
IDIX / Idenix Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Secur |
|
| July 21, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identify |
|
| July 21, 2014 |
IDIX / Idenix Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A- AMENDMENT NO. 5 SC 14D9/A- Amendment No. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title |
|
| July 11, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - AMENDMENT NO. 4 Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (id |
|
| July 11, 2014 |
IDIX / Idenix Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A - AMENDMENT NO. 4 SC 14D9/A - Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title |
|
| July 3, 2014 |
IDIX / Idenix Pharmaceuticals Inc SC 14D9/A - - SC 14D9/A (AMENDMENT NO. 3) SC 14D9/A (Amendment No. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title |
|
| July 3, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identify |
|
| June 27, 2014 |
SC 14D9/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title |
|
| June 27, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - AMENDMENT NO. 2 Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (id |
|
| June 26, 2014 |
- AMENDMENT NO.1 TO SCHEDULE 14D-9 Amendment No.1 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE ( |
|
| June 26, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identify |
|
| June 20, 2014 |
Letter of Brokers, Dealers Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of IDENIX PHARMACEUTICALS, INC. |
|
| June 20, 2014 |
Notice of Guaranteed Delivery Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of IDENIX PHARMACEUTICALS, INC. |
|
| June 20, 2014 |
Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 20, 2014 |
Summary Advertisement as published on June 20, 2014 Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| June 20, 2014 |
Merck Begins Tender Offer to Acquire Idenix Press Release dated June 20, 2014 Exhibit (a)(1)(I) News Release DRAFT: 6/18/2014 FOR IMMEDIATE RELEASE Media Contacts: Pamela Eisele Investor Contacts: Joe Romanelli (267) 305-3558 Steve Cragle (908) 423-3461 (908) 423-5185 Justin Holko (908) 423-5088 Merck Begins Tender Offer to Acquire Idenix WHITEHOUSE STATION, N. |
|
| June 20, 2014 |
Letter to Clients for use by Brokers, Dealers Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of IDENIX PHARMACEUTICALS, INC. |
|
| June 20, 2014 |
Letter of Transmittal Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of IDENIX PHARMACEUTICALS, INC. |
|
| June 20, 2014 |
Offer to Purchase, dated June 20, 2014 Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Idenix Pharmaceuticals, Inc. |
|
| June 20, 2014 |
Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (RULE 14D-100) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IDENIX PHARMACEUTICALS, INC. (Name of Subject Company) IMPERIAL BLUE CORPORATION (Offeror) MERCK & CO., INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE |
|
| June 17, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2014 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| June 17, 2014 |
EX-10.1 Exhibit 10.1 [IDENIX LETTERHEAD] November 23, 2010 CONFIDENTIAL Paul Fanning 17 Stable Way Medway, MA 02053 Dear Paul: This restatement to your Employment Letter of February 24, 2004, is made this 23rd day of November, 2010 between you and Idenix Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware (together with its successors and assigns, the “Company |
|
| June 13, 2014 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Idenix Pharmaceuticals, Inc., a Delaware corporation, and further agre |
|
| June 13, 2014 |
IDIX / Idenix Pharmaceuticals Inc / Merck & Co., Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 45166R 20 4 (CUSIP Number) Copies to: Geralyn S. Ritter Senior Vice President, Global Public Policy and Corporate Responsibility, Secretary and Assistant General Cou |
|
| June 12, 2014 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45166R204 (CU |
|
| June 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 IDENIX PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) a wholly owned subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identifying status as offeror, issue |
|
| June 9, 2014 |
Merck Announces Acquisition of Idenix EX-99.(A)(2) 3 d740687dex99a2.htm EX-99.(A)(2) Exhibit (a)(2) Merck Announces Acquisition of Idenix June 9, 2014 Forward-Looking Statement This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the timing and closing of the |
|
| June 9, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d740878d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Inc |
|
| June 9, 2014 |
SC14D9C - Q&A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45166R2 |
|
| June 9, 2014 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Idenix Pharmaceuticals, Inc. (Name of Subject Company) Idenix Pharmaceuticals, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 45166R204 (CU |
|
| June 9, 2014 |
EX-99.1 Exhibit 99.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of June 8, 2014, is entered into by and among Merck & Co., Inc., a New Jersey corporation (“Parent”), Imperial Blue Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and The Baupost Group, L.L.C., a Massachusetts limited liability corporation (the “Stockholder”). All |
|
| June 9, 2014 |
- SC14D9C - LETTER TO EMPLOYEES SC14D9C - Letter to Employees UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 9, 2014 |
EX-99.(a)(1) Exhibit (a)(1) News Release FOR IMMEDIATE RELEASE Merck Media Contact: Pamela Eisele (267) 305-3558 Investor Contact: Joe Romanelli (908) 423-5185 Steve Cragle (908) 423-3462 Justin Holko (908) 423-5088 Idenix Media/Investor Contact: Teri Dahlman (617) 995-9807 Merck to Acquire Idenix Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATI |
|
| June 9, 2014 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among IDENIX PHARMACEUTICALS, INC., MERCK & CO., INC. and IMPERIAL BLUE CORPORATION Dated as of June 8, 2014 TABLE OF CONTENTS Page ARTICLE I The Offer and the Merger; Closing; Effective Time 1.1 The Offer 2 1.2 Company Action 4 1.3 The Merger 6 1.4 Closing 6 1.5 Effective Time 6 ARTICLE II Certificate of Incorporation and Bylaws of the Surviving Cor |
|
| June 9, 2014 |
EX-99.2 Exhibit 99.2 News Release FOR IMMEDIATE RELEASE Merck Media Contact: Pamela Eisele Investor Contact: Joe Romanelli (267) 305-3558 (908) 423-5185 Steve Cragle Justin Holko (908) 423-3462 (908) 423-5088 Idenix Media/Investor Contact: Teri Dahlman (617) 995-9807 Merck to Acquire Idenix Acquisition Expands Portfolio of Promising Investigational Therapies for Hepatitis C WHITEHOUSE STATION, N.J |
|
| June 9, 2014 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Idenix Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) IMPERIAL BLUE CORPORATION (Offeror) A Wholly Owned Subsidiary of MERCK & CO., INC. (Offeror) (Names of Filing Persons (identifying status as offero |
|
| June 6, 2014 |
IDENIX PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN February 11, 2014 EX-99.1 Exhibit 99.1 IDENIX PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN February 11, 2014 The purpose of this Plan is to provide eligible employees of Idenix Pharmaceuticals, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, $0.001 par value (the “Common Stock”), commencing on July 1, 2014. Two Million (2,000,000) |
|
| June 6, 2014 |
S-8 1 d730518ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 6, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IDENIX PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-0478605 (State or Other Jurisdiction of Incorp |
|
| June 6, 2014 |
Submission of Matters to a Vote of Security Holders - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2014 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation o |
|
| May 1, 2014 |
IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS AND HCV PIPELINE REVIEW EX-99.1 2 d719370dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS AND HCV PIPELINE REVIEW CAMBRIDGE, Mass., May 1, 2014 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of h |
|
| May 1, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d719370d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of |
|
| May 1, 2014 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2014 |
Acceleration Request IDENIX PHARMACEUTICALS, INC. 320 Bent Street Cambridge, MA 02141 April 30, 2014 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Idenix Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-194190 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Se |
|
| April 29, 2014 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 7, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Com |
|
| April 7, 2014 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C • Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437 • Idenix on Track to Initiate All-Oral Pan-Genotypic Phase II Combinati |
|
| April 3, 2014 |
IDIX / Idenix Pharmaceuticals Inc / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Julie Pender Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 696 4509 With a copy to: Peter Harwich Allen & Overy LLP |
|
| April 3, 2014 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2014 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| March 24, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 d700554d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction |
|
| March 24, 2014 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case CAMBRIDGE, Mass., March 24, 2014 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral d |
|
| March 14, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 d695364d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction |
|
| March 14, 2014 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman [email protected] IDENIX PHARMACEUTICALS FILES PATENT INFRINGEMENT LAWSUITS AGAINST GILEAD SCIENCES IN EUROPE Granted European Patent Covering 2’-Methyl-2’-Fluoro Nucleosides for Treating Hepatitis C Virus CAMBRIDGE, Mass., March 14, 2014 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutica |
|
| February 27, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Date of Report (Date of earliest event reported): February 27, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Commission File |
|
| February 27, 2014 |
EX-4.2 Exhibit 4.2 IDENIX PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314( |
|
| February 27, 2014 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on February 27, 2014 Registration No. |
|
| February 27, 2014 |
Form of Subordinated Note (FACE OF SECURITY) EX-4.4 Exhibit 4.4 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| February 27, 2014 |
EX-10.46 Exhibit 10.46 [Idenix Letterhead] September 9, 2013 David Standring 205 Gun Hill Street Milton, MA 02186 Dear David: As we have discussed, your employment with Idenix Pharmaceuticals, Inc. (“Idenix” or the “Company”) will end on September 9, 2013. The Company will provide you with the severance benefits described in paragraph 2 below if you sign and return this letter agreement (the “Agre |
|
| February 27, 2014 |
10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2014 |
EX-12 7 d675389dex12.htm EX-12 Exhibit 12 STATEMENT REGARDING COMPUTATION OF RATIO/DEFICIENCY OF EARNINGS TO FIXED CHARGES ( In Thousands) For the Year Ended December 31, 2013 2012 2011 2010 2009 Loss: Loss before income taxes $ (122,370 ) $ (32,489 ) $ (52,040 ) $ (61,595 ) $ (53,168 ) Add: fixed charges 135 76 163 159 146 Total loss $ (122,235 ) $ (32,413 ) $ (51,877 ) $ (61,436 ) $ (53,022 ) Fi |
|
| February 27, 2014 |
IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2013 FINANCIAL RESULTS CAMBRIDGE, Mass., February 27, 2014 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today rep |
|
| February 27, 2014 |
EX-4.1 Exhibit 4.1 IDENIX PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.0 |
|
| February 27, 2014 |
Form of Senior Note (FACE OF SECURITY) EX-4.3 Exhibit 4.3 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| February 27, 2014 |
EX-21.1 Exhibit 21.1 Subsidiaries of the Company Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Idenix (Massachusetts) Inc. Massachusetts Idenix Securities Corporation Massachusetts Idenix (Cayman) Limited Cayman Islands Idenix SARL** France ** Wholly-owned by Idenix (Cayman) Limited |
|
| February 14, 2014 |
IDIX / Idenix Pharmaceuticals Inc / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Julie Pender Novartis Pharma AG Lichtstrasse 35 CH-4056 Basel, Switzerland +41 61 696 4509 With a copy to: Peter Harwich Allen & Overy LLP |
|
| February 14, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2014 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporat |
|
| February 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* IDENIX PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S |
|
| February 4, 2014 |
IDIX / Idenix Pharmaceuticals Inc / BAUPOST GROUP LLC/MA - IDIX13DAMEND1 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title Class of Securities) 45166R204 (Cusip Number) Seth A. Klarman The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700 Boston, Massachusetts 02116 (617) 210-8300 With a copy to: Jeffrey R. Katz, Esq Rop |
|
| January 30, 2014 |
EX-99.1 2 d666307dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS ANNOUNCES DECISION BY THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD IN THE FIRST PATENT INTERFERNCE CAMBRIDGE, Mass., January 29, 2014 — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged |
|
| January 30, 2014 |
Financial Statements and Exhibits, Other Events 8-K 1 d666307d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Juris- dic |
|
| January 28, 2014 |
IDENIX TO RAISE $106.7 MILLION THROUGH REGISTERED DIRECT OFFERING EX-99.1 5 d665213dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX TO RAISE $106.7 MILLION THROUGH REGISTERED DIRECT OFFERING CAMBRIDGE, Mass., Jan. 28, 2014 – Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, tod |
|
| January 28, 2014 |
16,420,241 shares Common Stock 424B5 Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. |
|
| January 28, 2014 |
Baupost Capital, L.L.C. 10 St. James Avenue, Suite 1700 Boston, MA 0211 January 27, 2014 EX-10.2 4 d665213dex102.htm EX-10.2 Exhibit 10.2 Baupost Capital, L.L.C. 10 St. James Avenue, Suite 1700 Boston, MA 0211 January 27, 2014 Idenix Pharmaceuticals, Inc. 320 Bent Street Cambridge, MA 02141 Attn: Ronald C. Renaud, Jr. Dear Mr. Renaud: Reference is made to that certain Subscription Agreement, dated as of January 27, 2014, by and between Idenix Pharmaceuticals, Inc., a Delaware corporat |
|
| January 28, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d665213d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdicti |
|
| January 28, 2014 |
[SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT] EX-10.1 3 d665213dex101.htm EX-10.1 Exhibit 10.1 January 27, 2014 Idenix Pharmaceuticals, Inc. 320 Bent Street Cambridge, Massachusetts 02141-2025 Ladies and Gentlemen: Each of the undersigned (each, an “Investor” and collectively, the “Investors”) hereby confirms and agrees, severally and not jointly, with you as follows: 1. This Purchase Agreement (together with the attached schedule and annexes |
|
| January 27, 2014 |
S-3MEF 1 d667224ds3mef.htm S-3MEF As filed with the Securities and Exchange Commission on January 27, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0478605 (State or other jurisdiction o |
|
| January 13, 2014 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman, (617) 995-9807 Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir CAMBRIDGE, Mass., Jan. 13, 2014 — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical com |
|
| January 13, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation ( |
|
| January 6, 2014 |
EX-10.1 Exhibit 10.1 [IDENIX LETTERHEAD] December 30, 2013 CONFIDENTIAL Jacques Dumas 32 Suffolk Lane Carlisle, MA 01741 Dear Jacques: This employment letter (the “letter”) is made by and between Idenix Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware (together with its successors and assigns, the “Company”), and you (and, together with the Company, the “Pa |
|
| January 6, 2014 |
8-K 1 d654685d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other juris |
|
| December 9, 2013 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS ANNOUNCES DECLARATION OF SENIOR PARTY IN A SECOND PATENT INTERFERENCE BY THE USPTO CAMBRIDGE, Mass., December 9, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human vira |
|
| December 9, 2013 |
Financial Statements and Exhibits, Other Events 8-K 1 d639723d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Juris- dic |
|
| December 2, 2013 |
IDENIX PHARMACEUTICALS FILES PATENT INFRINGEMENT AND INTERFERENCE LAWSUITS AGAINST GILEAD SCIENCES EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman, [email protected] IDENIX PHARMACEUTICALS FILES PATENT INFRINGEMENT AND INTERFERENCE LAWSUITS AGAINST GILEAD SCIENCES CAMBRIDGE, Mass., December 2, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human |
|
| December 2, 2013 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Commi |
|
| November 1, 2013 |
IDIX / Idenix Pharmaceuticals Inc / BAUPOST GROUP LLC/MA - IDIX13DORIG Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title Class of Securities) 45166R204 (Cusip Number) Seth A. Klarman The Baupost Group, L.L.C. 10 St. James Avenue, Suite 1700 Boston, Massachusetts 02116 (617) 210-8300 With a copy to: Gregory D. Sheehan, Esq Ropes and Gray LLP |
|
| October 30, 2013 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTH 2013 FINANCIAL RESULTS AND PROVIDES HCV PIPELINE UPDATE • Enrollment initiated for a phase I/II clinical trial for IDX21437, a next-generation uridine nucleotide prodrug inhibitor for the treatment of hepatitis C virus infection (HCV) • |
|
| October 30, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d621388d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdicti |
|
| October 30, 2013 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 30, 2013 |
EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is entered into as of this 3rd day of September, 2013, by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”), and IDENIX PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant entered into that certain Lease dated as o |
|
| September 10, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation or or |
|
| August 7, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Co |
|
| August 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2013 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000 |
|
| August 7, 2013 |
IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2013 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2013 FINANCIAL RESULTS CAMBRIDGE, Mass., August 7, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reporte |
|
| August 7, 2013 |
EX-10.2 3 d558252dex102.htm EX-10.2 Exhibit 10.2 CONFIDENTIAL FIRST AMENDMENT to CLINICAL TRIAL COLLABORATION AGREEMENT between Idenix Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., This first Amendment (the “First Amendment”) to the Clinical Trial Collaboration Agreement (as defined below) shall be effective as of the last of the last signature affixed hereto (“First Amendment Effective |
|
| August 7, 2013 |
EX-10.1 2 d558252dex101.htm EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 1st day of May, 2013, by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”), and IDENIX PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant entered into that certain Lea |
|
| June 10, 2013 |
IDENIX PHARMACEUTICALS APPOINTS CHARLES ROWLAND TO ITS BOARD OF DIRECTORS Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman, (617) 995-9807 IDENIX PHARMACEUTICALS APPOINTS CHARLES ROWLAND TO ITS BOARD OF DIRECTORS CAMBRIDGE, Mass., June 10, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has ap |
|
| June 10, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation o |
|
| June 10, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation o |
|
| April 30, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Co |
|
| April 30, 2013 |
IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contact: Teri Dahlman (617) 995-9807 IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS CAMBRIDGE, Mass., April 30, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial r |
|
| April 30, 2013 |
Exhibit 21.1 Subsidiaries of the Company Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Idenix (Massachusetts) Inc. Massachusetts Idenix Securities Corporation Massachusetts Idenix (Cayman) Limited Cayman Islands Idenix SARL** France ** Wholly-owned by Idenix (Cayman) Limited |
|
| April 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2013 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 26, 2013 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 25, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Co |
|
| March 25, 2013 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS ANNOUNCES DECISION BY THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD IN THE FIRST PHASE OF THE INTERFERENCE CAMBRIDGE, Mass., March 22, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biophar |
|
| February 26, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act Date of Report (Date of earliest event reported): February 25, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Commiss |
|
| February 26, 2013 |
IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2012 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR ENDED 2012 FINANCIAL RESULTS CAMBRIDGE, Mass., February 25, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for |
|
| February 26, 2013 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporat |
|
| February 25, 2013 |
Exhibit 21.1 Subsidiaries of the Company Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Idenix (Massachusetts) Inc. Massachusetts Idenix Massachusetts Securities Corporation Massachusetts Idenix (Cayman) Limited Cayman Islands Idenix SARL** France ** Wholly-owned by Idenix (Cayman) Limited |
|
| February 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-498 |
|
| February 25, 2013 |
Exhibit 10.24 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. CLINICAL TRIAL COLLABORATION AGREEMENT This CLINICAL TRIAL COLLABORATION AGREEMENT (the ?Agreement?) is made and entered into as of the date of the last signature affixed hereto (the ?Effective Date?) by and between Idenix Pharmaceuticals, Inc., a Delaware corp |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Fi |
|
| February 11, 2013 |
SC 13G/A 1 idix13gadec12.htm IDIX AS OF 12/31/2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* IDENIX PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate |
|
| February 8, 2013 |
IDIX / Idenix Pharmaceuticals Inc / BAUPOST GROUP LLC/MA - IDIX13GAMEND2 Passive Investment CUSIP NO. 45166R204 13G PAGE 1 OF 11 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Janu |
|
| February 5, 2013 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Teri Dahlman (617) 995-9807 or [email protected] IDENIX PHARMACEUTICALS PROVIDES UPDATE ON IDX184 AND IDX19368 DEVELOPMENT PROGRAMS - Management to host a conference call and webcast today at 4:30 pm ET - CAMBRIDGE, Mass., February 4, 2013 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company e |
|
| February 5, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation ( |
|
| January 28, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2013 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporati |
|
| January 9, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2013 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (C |
|
| December 26, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 19, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporat |
|
| November 9, 2012 |
IDIX / Idenix Pharmaceuticals Inc / BAUPOST GROUP LLC/MA - IDIX13GAMEND1 Passive Investment CUSIP NO. 45166R204 13G PAGE 1 OF 10 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) Octob |
|
| November 1, 2012 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTH 2012 FINANCIAL RESULTS AND HCV PROGRAM UPDATE CAMBRIDGE, Mass., November 1, 2012 - Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and deve |
|
| November 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation ( |
|
| November 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2012 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 1, 2012 |
EX-21.1 Exhibit 21.1 Subsidiaries of the Company Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Idenix (Massachusetts) Inc. Massachusetts Idenix Massachusetts Securities Corporation Massachusetts Idenix (Cayman) Limited Cayman Islands Idenix SARL** France ** Wholly-owned by Idenix (Cayman) Limited 56 |
|
| September 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation or o |
|
| September 28, 2012 |
Termination Agreement Exhibit 10.2 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of this 25th day of September, 2012 (the “Execution Date”), by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company (“Landlord,” as successor-in-interest to Metropolitan Life Insurance Company (“Prior Landlord”), as successor-in-interest to BHX, LLC, |
|
| September 28, 2012 |
Lease Agreement Exhibit 10.1 LEASE by and between BMR-ROGERS STREET LLC, a Delaware limited liability company and IDENIX PHARMACEUTICALS, INC., a Delaware corporation LEASE THIS LEASE (this “Lease”) is entered into as of this 25th day of September, 2012 (the “Execution Date”), by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”), and IDENIX PHARMACEUTICALS, INC., |
|
| September 20, 2012 |
EX-99.1 Exhibit 99.1 1 Investor Presentation September 20, 2012 2 Building a Leading Antiviral Franchise Safe Harbor Statement This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processes and market opportunities. These forward- looking stateme |
|
| September 20, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Juris-diction of Incorporatio |
|
| September 19, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation |
|
| September 19, 2012 |
EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF IDENIX PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxies 3 1.9 Action at Meeting 3 1.10 Nomination of Directors. 4 1.11 Notice of Business at Annual Meetings. |
|
| August 27, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Commission |
|
| August 27, 2012 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Daniella Beckman (617) 224-4471 (investors) IDENIX PROVIDES UPDATE ON IDX19368 DEVELOPMENT PROGRAM - IDX19368, for which Idenix has submitted an IND application, has been placed on clinical hold by FDA – CAMBRIDGE, Mass., August 27, 2012 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmac |
|
| August 17, 2012 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Daniella Beckman (617) 224-4471 (investors) IDENIX PROVIDES UPDATE ON IDX184 CLINICAL DEVELOPMENT PROGRAM - IDX184 has been placed on partial clinical hold by FDA – Management to host a conference call webcast today at 8:30 am ET CAMBRIDGE, Mass., August 16, 2012 — Idenix Pharmaceuticals, |
|
| August 17, 2012 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (C |
|
| August 10, 2012 |
Exhibit 4 Novartis Novartis AG Lichtstrasse 35 CH 4056 Basel August 8, 2012 The undersigned hereby certifies that Dr. Martin Henrich and Knut Mager are authorized to execute Amendment No. 7 to Schedule 13D with respect to Idenix Pharmaceuticals, Inc., on behalf of Novartis AG. /s/ Peter Rupprecht Name: Peter Rupprecht Title: Senior Corporate Counsel |
|
| August 10, 2012 |
EX-2 2 a12-177991ex2.htm EX-2 Exhibit 2 EXECUTION VERSION Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. TERMINATION AND REVISED RELATIONSHIP AGREEMENT This Termination and Revised Relationship Agreement (this “Agreement”), effective as of July 31, 2012 (the “Effective Date”), is made by and among Idenix Pharmaceuticals, |
|
| August 10, 2012 |
EX-3 3 a12-177991ex3.htm EX-3 Exhibit 3 LOCK-UP AGREEMENT July 31, 2012 J. P. MORGAN SECURITIES LLC As Representative of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Re: Idenix Pharmaceuticals, Inc. — Public Offering Ladies and Gentlemen: The undersigned understands that you, as R |
|
| August 10, 2012 |
IDIX / Idenix Pharmaceuticals Inc / NOVARTIS AG - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R 20 4 (CUSIP Number) Thomas Lynch, Esq. Adam H. Golden, Esq. Novartis Pharma AG Kaye Scholer LLP Lichtstrasse 35 425 Park Avenue CH-4056 Basel, Switzerland |
|
| August 8, 2012 |
Exhibit 10.2 Idenix Pharmaceuticals, Inc. Incentive Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Idenix Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), on , 2012 (the ?Grant Date?) to [ ] (the ?Participant?), of an option to purchase, in whole or in part, on the terms provided herein and in the Company?s 201 |
|
| August 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2012 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000 |
|
| August 8, 2012 |
Exhibit 10.3 Idenix Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2012 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Idenix Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), on , 2012 (the ?Grant Date?) to [ ], an [employee], [consultant], [director] of the Company (the ?Participant?), of an option to purchase, in whole or in |
|
| August 8, 2012 |
IDENIX PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN Exhibit 10.1 IDENIX PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2012 Stock Incentive Plan (the ?Plan?) of Idenix Pharmaceuticals, Inc. a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| August 8, 2012 |
TERMINATION AND REVISED RELATIONSHIP AGREEMENT Exhibit 10.4 EXECUTION VERSION Confidential materials omitted and filed separately with the Securities and Exchange commission. Asterisks denote omissions. TERMINATION AND REVISED RELATIONSHIP AGREEMENT This Termination and Revised Relationship Agreement (this ?Agreement?), effective as of July 31, 2012 (the ?Effective Date?), is made by and among Idenix Pharmaceuticals, Inc., with offices at 60 H |
|
| August 3, 2012 |
Idenix Pharmaceuticals Prices Public Offering of Common Stock Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Daniella Beckman (617) 224-4471 (investors) Idenix Pharmaceuticals Prices Public Offering of Common Stock CAMBRIDGE, Mass., August 2, 2012—Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral di |
|
| August 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| August 3, 2012 |
IDENIX PHARMACEUTICALS, INC. 22,000,000 Shares of Common Stock Underwriting Agreement Underwriting Agreement Exhibit 1.1 Execution Version IDENIX PHARMACEUTICALS, INC. 22,000,000 Shares of Common Stock Underwriting Agreement August 2, 2012 J. P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Idenix Pharmaceuticals, Inc., a Delaware corpo |
|
| August 2, 2012 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-182953 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock; $.001 par value 25,300,000 $ 8.00 $ 202,400,000 $ 23,195 (1) Assumes e |
|
| July 31, 2012 |
Exhibit 99.1 Changes to Collaboration with Novartis July 2012 Description 2003 Original Agreement Terms 2012 Termination & Revised Relationship Agreement Terms Pipeline Rights NVS had exclusive WW option to license all clinical products in IDIX pipeline if maintained above 30% ownership NVS had 50% co-marketing rights in US and Big 5 EU, exclusive commercialization ROW IDIX has WW rights to curren |
|
| July 31, 2012 |
Form of Senior Indenture Exhibit 4.1 IDENIX PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313( |
|
| July 31, 2012 |
EX-99.1 Exhibit 99.1 Risk Factors Our business faces many risks. The risks described below may not be the only risks we face. Additional risks we do not yet know of or which we currently believe are immaterial may also impair our business operations. If any of the events or circumstances described in the following risks actually occurs, our business, financial condition or results of operations co |
|
| July 31, 2012 |
Form of Subordinated Indenture Exhibit 4.2 IDENIX PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313( |
|
| July 31, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| July 31, 2012 |
Form of Subordinated Note (FACE OF SECURITY) Form of Subordinated Note Exhibit 4.4 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPO |
|
| July 31, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| July 31, 2012 |
Form of Senior Note (FACE OF SECURITY) Form of Senior Note Exhibit 4.3 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR AN |
|
| July 31, 2012 |
Exhibit 10.1 EXECUTION COPY IDENIX PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT July 31, 2012 TABLE OF CONTENTS Page SECTION 1 DEFINITIONS 1 1.1 Definitions 1 SECTION 2 REGISTRATION RIGHTS 5 2.1 Requested Registration 5 2.2 Company Registration. 8 2.3 Expenses of Registration 8 2.4 Registration Procedures 9 2.5 Registration on Form S-3. 12 2.6 Indemnification. 13 2.7 I |
|
| July 31, 2012 |
Exhibit 12 STATEMENT REGARDING COMPUTATION OF RATIO/DEFICIENCY OF EARNINGS TO FIXED CHARGES ( In Thousands) Three Months Ended For the Year Ended December 31, March 31, 2012 2011 2010 2009 2008 2007 Earnings (loss): Income (loss) before income taxes $ 11,450 $ (52,040 ) $ (61,595 ) $ (53,168 ) $ (70,162 ) $ (82,269 ) Add: Fixed Charges 5 163 159 146 150 177 Total earnings (loss) $ 11,455 $ (51,877 |
|
| July 31, 2012 |
Table of Contents As filed with the Securities and Exchange Commission on July 31, 2012 Registration No. |
|
| July 31, 2012 |
Sole book-running manager J.P. Morgan Lead manager Leerink Swann 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-182953 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale i |
|
| June 20, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Com |
|
| June 20, 2012 |
Press Release dated June 19, 2012 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719 — In an interim analysis from an ongoing phase IIb clinical trial of IDX184, an HCV nucleotide inhibitor, 89% of patients who completed an ad |
|
| June 11, 2012 |
IDENIX PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN Exhibit 99.1 IDENIX PHARMACEUTICALS, INC. 2012 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2012 Stock Incentive Plan (the “Plan”) of Idenix Pharmaceuticals, Inc. a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| June 11, 2012 |
As filed with the Securities and Exchange Commission on June 11, 2012 Registration No. |
|
| June 8, 2012 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation or organiz |
|
| May 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation or organiz |
|
| May 2, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Juris- diction of Incorporation (Commission F |
|
| May 2, 2012 |
Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS AND HCV DEVELOPMENT PROGRAM PROGRESS CAMBRIDGE, Mass., May 2, 2012 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and deve |
|
| May 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2012 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-49839 Idenix Pha |
|
| April 25, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy S |
|
| April 24, 2012 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2012 Idenix Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-49839 45-0478605 (State or Other Jurisdiction of Incorporation (Co |
|
| April 24, 2012 |
Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS PROVIDES UPDATE ON HEPATITIS C CLINICAL DEVELOPMENT PROGRAMS - IDX719 demonstrates pan-genotypic activity at single doses in HCV-infected patients achieving greater than 3 log10 viral load reductions in the 100 mg dose g |
|
| March 29, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 27, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation |
|
| March 6, 2012 |
Exhibit 10.12 Exhibit 10.12 FIFTH AMENDMENT OF LEASE THIS FIFTH AMENDMENT OF LEASE is made as of this day of , 2011 between RB KENDALL FEE, LLC, a Delaware limited liability company having a mailing address c/o The Beal Companies, LLP, 177 Milk Street, Boston, Massachusetts (“Landlord”) and IDENIX PHARMACEUTICALS, INC., having a mailing address at 60 Hampshire Street, Cambridge, Massachusetts 0213 |
|
| March 6, 2012 |
Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Idenix (Massachusetts) Inc. Massachusetts Idenix (Cayman) Limited Cayman Islands Idenix SARL* France * Wholly-owned by Idenix (Cayman) Limited |
|
| March 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-498 |
|
| March 6, 2012 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS ELECTS THOMAS HODGSON AS CHAIRMAN OF THE BOARD AND APPOINTS MICHAEL WYZGA TO ITS BOARD OF DIRECTORS Cambridge, MA, March 1, 2012 - Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discove |
|
| March 6, 2012 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation o |
|
| February 23, 2012 |
Exhibit 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE CAMBRIDGE, Mass., February 23, 2012 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discove |
|
| February 23, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2012 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2012 |
Amendment No.2 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2011 ( |
|
| February 10, 2012 |
IDIX / Idenix Pharmaceuticals Inc / BAUPOST GROUP LLC/MA - IDIX13GORIG Passive Investment CUSIP NO. 45166R204 13G PAGE 1 OF 10 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2011 (Date |
|
| February 10, 2012 |
IDIX / Idenix Pharmaceuticals Inc / PRICE T ROWE ASSOCIATES INC /MD/ - 12/31/2011 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IDENIX PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166R204 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S |
|
| February 6, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2012 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporati |
|
| February 3, 2012 |
IDENIX ANNOUNCES REMOVAL OF THE PARTIAL CLINICAL HOLD ON HCV NUCLEOTIDE INHIBITOR, IDX184 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX ANNOUNCES REMOVAL OF THE PARTIAL CLINICAL HOLD ON HCV NUCLEOTIDE INHIBITOR, IDX184 CAMBRIDGE, Mass., February 3, 2012 — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs |
|
| February 3, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2012 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporati |
|
| January 9, 2012 |
Exhibit 99.2 Exhibit 99.2 1 Interim IDX184 Phase IIb Data and Development Pipeline Update Conference Call January 9, 2012 2 Building a Leading Antiviral Franchise Safe Harbor Statement This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processe |
|
| January 9, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2012 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other Jurisdiction of Incorporatio |
|
| January 9, 2012 |
IDENIX REPORTS POSITIVE INTERIM DATA FOR HCV NUCLEOTIDE INHIBITOR, IDX184 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Teri Dahlman (617) 995-9807 (investors) IDENIX REPORTS POSITIVE INTERIM DATA FOR HCV NUCLEOTIDE INHIBITOR, IDX184 • No serious adverse events observed in phase IIb study of IDX184; Data Safety Monitoring Board (DSMB) recommends continuation of the clinical trial • In the 100 mg IDX184 arm, 73% of |
|
| December 22, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2011 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporat |
|
| December 15, 2011 |
Exhibit 1 LOCK-UP AGREEMENT November l5, 2011 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, NY 10179 Re: Idenix Pharmaceuticals, Inc. ? Public Offering Ladies and Gentlemen: The undersigned understands that you propose to enter into an Underwriting Agreement (the ?Underwriting Agreement?) with Idenix Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), providing for the public |
|
| December 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R 20 4 (CUSIP Number) Matt Owens, Esq. Adam H. Golden, Esq. Novartis Pharma AG Kaye Scholer LLP Lichtstrasse 35 425 Park Avenue CH-4056 Basel, Switzerland Ne |
|
| November 16, 2011 |
IDENIX PHARMACEUTICALS, INC. 9,393,416 Shares of Common Stock Underwriting Agreement exv1w1 EXHIBIT 1.1 Execution Version IDENIX PHARMACEUTICALS, INC. 9,393,416 Shares of Common Stock Underwriting Agreement November 16, 2011 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Idenix Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”), an aggregate of 9,393,416 shares of common |
|
| November 16, 2011 |
FWP 1 b88933bfwp.htm FWP Issuer Free Writing Prospectus dated November 16, 2011 Filed Pursuant to Rule 433 Registration No. 333-177167 (Relating to Preliminary Prospectus Supplement dated November 15, 2011) We have filed with the Securities and Exchange Commission (the “SEC”) a registration statement and a preliminary prospectus supplement (together with the prospectus dated October 14, 2011, the |
|
| November 16, 2011 |
e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 16, 2011 |
Idenix Pharmaceuticals Prices Public Offering of Common Stock exv99w1 Exhibit 99.1 Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Eric Hoffman (617) 224-4485 (investors) Idenix Pharmaceuticals Prices Public Offering of Common Stock CAMBRIDGE, Mass., November 16, 2011 —Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today |
|
| November 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 45166R204 (CUSIP Number) October 27, 2011 (Date of Event Which Requires Fil |
|
| November 16, 2011 |
Sole book-running manager J.P. Morgan Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-177167 Prospectus supplement (To Prospectus dated October 14, 2011) 9,393,416 shares Common Stock We are offering 9,393,416 shares of common stock. Shares of our common stock trade on The NASDAQ Global Market under the symbol ?IDIX?. The last reported sale price on November 15, 2011 was $7.15 per share. Per Share Total Pu |
|
| November 15, 2011 |
Sole book-running manager J.P. Morgan Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 2, 2011 |
Exhibit 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Eric Hoffman (617) 224-4485 (investors) IDENIX PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTH 2011 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ — Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in th |
|
| November 2, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2011 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporati |
|
| October 12, 2011 |
As filed with the Securities and Exchange Commission on October 12, 2011 S-3/A 1 b87938bsv3za.htm S-3/A As filed with the Securities and Exchange Commission on October 12, 2011 Registration No. 333-177167 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO 1. TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0478605 (State o |
|
| October 4, 2011 |
As filed with the Securities and Exchange Commission on October 4, 2011 S-3 1 b87938sv3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on October 4, 2011 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0478605 (State or other ju |
|
| September 8, 2011 |
sc13gza SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* IDENIX PHARMACEUTICALS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45166R204 (CUSIP Number) August 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the Rule pursuant to which this Sch |
|
| August 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000 |
|
| August 9, 2011 |
EX-3.1 Certificate of Amendment of Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF IDENIX PHARMACEUTICALS, INC. Idenix Pharmaceuticals, Inc. (the ?Corporation?), organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: The Board of Directors of the Corporation duly adopted at a meeting duly called, pursuant to Section 242 of |
|
| August 8, 2011 |
Exhibit 99.1 Exhibit 99.1 IDENIX PHARMACEUTICALS REPORTS SECOND QUARTER AND SIX MONTH 2011 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE Cambridge, Mass., August 8, 2011 - • Lead nucleotide polymerase inhibitor IDX184 advancing clinically — The Company has initiated dosing of IDX184 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a Phase IIb hepatitis C virus (HCV) trial • |
|
| August 8, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2011 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other Jurisdiction of Incorporation |
|
| June 24, 2011 |
/s/ Daniella Beckman Daniella Beckman Exhibit 10.1 Exhibit 10.1 June 20, 2011 CONFIDENTIAL Daniella Beckman Dear Daniella: On behalf of Idenix Pharmaceuticals, Inc. (“Idenix” or the “Company”), I am pleased to offer you the position of Vice President, Chief Financial Officer and Treasurer, reporting directly to me as President and Chief Executive Officer. The terms of our employment offer are set forth below. 1. Commencement. Your pro |
|
| June 24, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2011 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation) |
|
| June 6, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2011 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other Jurisdiction of Incorporation) |
|
| April 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| April 27, 2011 |
IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Eric Hoffman (617) 224-4485 (investors) IDENIX PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS Cambridge, Mass., — April 27, 2011 - Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human vi |
|
| April 27, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2011 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other Jurisdiction of Incorporation |
|
| April 25, 2011 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2011 |
EX-99.1 2 a11-104481ex99d1.htm EX-99.1 Exhibit 1 GENERAL WAIVER AND CONSENT This General Waiver and Consent is made and effective as of the 6th of April, 2011 (“Effective Date”) between Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge, Massachusetts 02139, USA (“Idenix US”) and Novartis Pharma AG, with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novar |
|
| April 20, 2011 |
EX-99.6 3 a11-104481ex99d6.htm EX-99.6 Exhibit 6 LOCK-UP AGREEMENT April 6, 2011 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, NY 10179 Re: Idenix Pharmaceuticals, Inc. — Public Offering Ladies and Gentlemen: The undersigned understands that you propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Idenix Pharmaceuticals, Inc., a Delaware corporation (the “C |
|
| April 20, 2011 |
SC 13D/A 1 a11-104481sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45166R 20 4 (CUSIP Number) Matt Owens, Esq. Adam H. Golden, Esq. Novartis Pharma AG Kaye Scholer LLP Lichtstrasse 35 425 |
|
| April 18, 2011 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Idenix Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 45166R204 (CUSIP Number) April 8, 2011 (Date of Event Which Req |
|
| April 11, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2011 Idenix Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-49839 45-0478605 (State or other jurisdiction of incorporation) |
|
| April 11, 2011 |
IDENIX PHARMACEUTICALS, INC. 18,310,000 Shares of Common Stock Underwriting Agreement Exhibit 1.1 Exhibit 1.1 Execution Version IDENIX PHARMACEUTICALS, INC. 18,310,000 Shares of Common Stock Underwriting Agreement April 8, 2011 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10172 Ladies and Gentlemen: Idenix Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”), an aggregate of 18,310,000 shares of Com |
|
| April 11, 2011 |
Exhibit 10.1 Exhibit 10.1 CONCURRENT PRIVATE PLACEMENT STOCK PURCHASE AGREEMENT by and between NOVARTIS PHARMA AG and IDENIX PHARMACEUTICALS, INC. Table of Contents Page 1. Purchase and Sale of Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing 1 1.3 Delivery 2 1.4 Further Assurances 2 2. Representations and Warranties of the Company 2 2.1 Organization; Good Standing; Qualification 2 2.2 Au |
|
| April 11, 2011 |
Idenix Pharmaceuticals Prices Public Offering of Common Stock Exhibit 99.1 DRAFT- NOT FOR IMMEDIATE RELEASE Idenix Pharmaceuticals Contacts: Kelly Barry (617) 995-9033 (media) Eric Hoffman (617) 224-4485 (investors) Idenix Pharmaceuticals Prices Public Offering of Common Stock CAMBRIDGE, Mass., April 8, 2011 —Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human v |
|
| April 8, 2011 |
pre14a Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2011 |
FWP 1 b85926f1fwp.htm FWP Issuer Free Writing Prospectus dated April 8, 2011 Filed Pursuant to Rule 433 Registrations No. 333-153471 and 333-173374 (Relating to Preliminary Prospectus Supplement dated April 7, 2011) We have filed with the Securities and Exchange Commission (the “SEC”) a registration statement and a preliminary prospectus supplement (together with the prospectus dated October 17, 2 |
|
| April 8, 2011 |
FWP 1 b85926f2fwp.htm FWP Issuer Free Writing Prospectus dated April 8, 2011 Filed Pursuant to Rule 433 Registrations No. 333-153471 and 333-173374 (Relating to Preliminary Prospectus Supplement dated April 7, 2011) We have filed with the Securities and Exchange Commission (the “SEC”) a registration statement and a preliminary prospectus supplement (together with the prospectus dated October 17, 2 |
|
| April 8, 2011 |
As filed with the Securities and Exchange Commission on April 8, 2011 S-3MEF 1 b85926mfsv3mef.htm S-3MEF Table of Contents As filed with the Securities and Exchange Commission on April 8, 2011 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IDENIX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 45-0478605 (State or othe |
|
| April 8, 2011 |
Sole book-running manager J.P. Morgan Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-153471 Prospectus supplement (To Prospectus dated October 17, 2008) 18,310,000 shares Common Stock We are offering 18,310,000 shares of our common stock. Shares of our common stock trade on the Nasdaq Global Market under the symbol “IDIX”. The last reported sale price on April 7, 2011 was $3.24 per share. Concurrently with the |
